Last reviewed · How we verify
NPF-08 （1-day treatment）
NPF-08 is a small molecule that targets the SGLT2 receptor.
NPF-08 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | NPF-08 （1-day treatment） |
|---|---|
| Sponsor | Nihon Pharmaceutical Co., Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, NPF-08 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Study of NPF-08 in Patients Who Receive Colonoscopy (PHASE3)
- Phase I/II Clinical Trial of NPF-08 in Healthy Volunteers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPF-08 （1-day treatment） CI brief — competitive landscape report
- NPF-08 （1-day treatment） updates RSS · CI watch RSS
- Nihon Pharmaceutical Co., Ltd portfolio CI